Connection
Gregory Schwartz to Renin-Angiotensin System
This is a "connection" page, showing publications Gregory Schwartz has written about Renin-Angiotensin System.
|
|
Connection Strength |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_left.gif) |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_right.gif) |
|
0.162 |
|
|
|
-
Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.162